Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report

Ramos-Casals, 2014, Adult haemophagocytic syndrome, Lancet, 383, 1503, 10.1016/S0140-6736(13)61048-X Otrock, 2015, Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis, Am J Hematol, 90, 220, 10.1002/ajh.23911 Thomas, 2016, Haemophagocytic lymphohistiocytosis: an elusive syndrome, Clin Med, 16, 432, 10.7861/clinmedicine.16-5-432 Henter, 1997, HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society, Med Pediatr Oncol, 28, 342, 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H Henter, 2002, Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation, Blood, 100, 2367, 10.1182/blood-2002-01-0172 Henter, 2007, HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, Pediatr Blood Cancer, 48, 124, 10.1002/pbc.21039 Brisse, 2016, Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options, Br J Haematol, 174, 175, 10.1111/bjh.14144 La Rosee, 2015, Treatment of hemophagocytic lymphohistiocytosis in adults, Hematol Am Soc Hematol Educ Program, 2015, 190, 10.1182/asheducation-2015.1.190 Chellapandian, 2013, Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens, Br J Haematol, 162, 376, 10.1111/bjh.12386 Trottestam, 2011, Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol, Blood, 118, 4577, 10.1182/blood-2011-06-356261 Wang, 2015, Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis, Blood, 126, 2186, 10.1182/blood-2015-05-644914 Villarino, 2015, Mechanisms of Jak/STAT signaling in immunity and disease, J Immunol, 194, 21, 10.4049/jimmunol.1401867 Kiu, 2012, Biology and significance of the JAK/STAT signaling pathways, Growth Factors, 30, 88, 10.3109/08977194.2012.660936 Harrison, 2012, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 787, 10.1056/NEJMoa1110556 Verstovsek, 2012, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N Engl J Med, 366, 799, 10.1056/NEJMoa1110557 Zeiser, 2015, Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey, Leukemia, 29, 2062, 10.1038/leu.2015.212 Spoerl, 2014, Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease, Blood, 123, 3832, 10.1182/blood-2013-12-543736 Mackay-Wiggan, 2016, Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata, JCI Insight, 1, e89790, 10.1172/jci.insight.89790 Xing, 2014, Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition, Nat Med, 20, 1043, 10.1038/nm.3645 Jakafi (ruxolitinib) prescribing information. Wilmington, DE: Incyte Corporation; March 2016. Das, 2016, Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis, Blood, 127, 1666, 10.1182/blood-2015-12-684399 Maschalidi, 2016, Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice, Blood, 128, 60, 10.1182/blood-2016-02-700013